齐鲁晚报·齐鲁壹点记者于军队采购网了解到，12月15日，上药控股（锦州）有限公司上榜军队采购失信名单，处理部门为海后采购和资产管理局。处罚 生效范围（单位）：全军；处罚生效范围（品种）：全品种。 据失信处理公告内容，上药控股（锦州）有限公司的具体违规情形为"围标串标"。违规情况显示，经调查核实，上药控股（锦州）有限公司在参加项目编 号2024-JH13-W1002采购活动中，存在围标串标等违规行为。其处理编号为SX2025124439，违规处理状态：处罚期限内。 处理部门根据军队供应商管理相关规定，作出禁止其在3年内参加全军物资工程服务采购活动的处罚。以上处理自2025年12月15日起算。在禁止期内，其 时任法定代表人袁克华控股或管理的其他企业禁止参加上述范围军队采购活动，授权代表王子铭禁止代理其他供应商参加上述范围军队采购活动。 据上药控股（锦州）有限公司官网介绍，现公司是集药品分销、营销服务、医疗器械于一体的大型医药商业企业。公司药品主要经营中成药、化学药制 剂、化学原料药、抗生素、生化药品、生物制品、第二类精神药品制剂、蛋白同化制剂、肽类激素，年销售额9000万元左右。 国家企业信用信息公示系统显示，上 ...

Group 1 - The company, Baillie Gifford, plans to globally offer 8.6343 million shares, with 863,500 shares available in Hong Kong and 7.7708 million shares for international sale [1] - The subscription period is set from November 7 to November 12, with a maximum offer price of HKD 389.00 per share, and the entry fee is approximately HKD 39,292.31 for 100 shares [1] - The total expected fundraising amount is HKD 3.18 billion, with a net amount of HKD 3.018 billion, intended for research and development of biological drug candidates outside mainland China, establishing a global supply chain, and general corporate purposes [1] Group 2 - The company has introduced cornerstone investors including Bristol-Myers Squibb, OAP III (HK) Limited, GL China Long Equity Opportunities SPV L.P., Athos Capital Limited, and Franklin Templeton Investments, who will subscribe to approximately 638,900 shares at the offer price [1] - The company is expected to be listed on the main board on November 17, 2025, with joint sponsors including Goldman Sachs (Asia) LLC, J.P. Morgan Securities (Far East) Limited, and CITIC Securities (Hong Kong) Limited [1] Group 3 - The company's main business includes wholesale of biochemical drugs, biological products (excluding preventive biological products), chemical raw materials, antibiotic raw materials, traditional Chinese medicine, chemical drug formulations, and antibiotic formulations [2] - The net profits for the years 2023, 2024, and the first half of 2025 (ending June 30) are projected to be -780 million, 3.708 billion, and -1.118 billion respectively, with year-on-year changes of -176.40%, 575.02%, and -123.96% [2]